Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are a group of diseases characterised by necrotizing inflammation of small vessels such as arterioles, venules, and capillaries. ANCA-associated vasculitides (AAV) are referred to as small vessel vasculitides. Three AAV subgroups, namely granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA), are defined according to clinical features. The most common disease with renal involvement in AAV is MPA Approximately 90% of patients with MPA have renal involvement. While this rate is 70-80% in GPA, less than half of EGPA patients have renal involvement. Untreated survival in AAVs is less than one year. With appropriate immunosuppressive therapy, the 5-year renal survival rate is 70-75%. Without therapy, the prognosis is poor but treatments, typically immunosuppressants, have improved survival, albeit with considerable morbidity from glucocorticoids and other immunosuppressive medications. Current challenges include improving the measures of disease activity and risk of relapse, uncertainty about optimal therapy duration and a need for targeted therapies with fewer adverse effects. In this review, we described the treatment of renal involvement in AAV in line with current studies.

Department of Nephrology Charles University Faculty of Medicine and General University Hospital Prague Czech Republic

Meram Medical Faculty Department of Internal Medicine Division of Nephrology Necmettin Erbakan University Konya Turkey

Zobrazit více v PubMed

Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11. https://doi.org/10.1002/ART.37715 PubMed DOI

Nguyen Y, Pagnoux C, Karras A et al (2020) Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the french vasculitis study group registry. J Autoimmun 112:102467. https://doi.org/10.1016/J.JAUT.2020.102467 PubMed DOI

Holle JU, Gross WL, Latza U et al (2011) Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63(1):257–266. https://doi.org/10.1002/ART.27763 PubMed DOI

Tesar V, Hruskova Z (2022) Extrarenal complications of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) and their impact on the outcome of the patients. J Nephrol. https://doi.org/10.1007/S40620-022-01250-Y PubMed DOI

Jennette JC, Falk RJ (1997) Small-vessel vasculitis. N Engl J Med 337(21):1512–1523. https://doi.org/10.1056/NEJM199711203372106 PubMed DOI

Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116(6):488–498. https://doi.org/10.7326/0003-4819-116-6-488 PubMed DOI

Aydin Z, Turkmen K, Dede F et al (2021) Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish society of nephrology-glomerular diseases (TSN-GOLD) Working Group. Clin Exp Nephrol 25(2):173–183. https://doi.org/10.1007/S10157-020-01978-6 PubMed DOI

Flossmann O, Berden A, De Groot K et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488–494. https://doi.org/10.1136/ARD.2010.137778 PubMed DOI

Geetha D, Jefferson JA (2020) ANCA-associated vasculitis: core curriculum. Am J Kidney Dis 75(1):124–137. https://doi.org/10.1053/J.AJKD.2019.04.031 PubMed DOI

Rovin BH, Adler SG, Barratt J et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4):S1–S276. https://doi.org/10.1016/J.KINT.2021.05.021/ATTACHMENT/D54815F6-C088-4C3F-A044-CFC19E0C0544/MMC1.PDF DOI

Aasarød K, Bostad L, Hammerstrøm J, Jørstad S, Iversen BM (2001) Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 16(5):953–960. https://doi.org/10.1093/NDT/16.5.953 PubMed DOI

Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21(10):1628–1636. https://doi.org/10.1681/ASN.2010050477 PubMed DOI

Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383(27):2628–2638. https://doi.org/10.1056/NEJMOA2026834 PubMed DOI PMC

Muratore F, Marvisi C, Castrignanò P et al (2022) VEXAS syndrome: a case series from a single-center cohort of italian patients with vasculitis. Arthritis Rheumatol (Hoboken, Nj). 74(4):665. https://doi.org/10.1002/ART.41992 DOI

Vandenbussche C, Bitton L, Bataille P et al (2019) Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis. Am J Nephrol 49(6):479–486. https://doi.org/10.1159/000500352 PubMed DOI

Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(2):542–548. https://doi.org/10.1002/ART.33361 PubMed DOI

Karras A, Pagnoux C, Haubitz M et al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76(10):1662–1668. https://doi.org/10.1136/ANNRHEUMDIS-2017-211123 PubMed DOI

Mukhtyar C, Flossmann O, Hellmich B et al (2008) Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 67(7):1004–1010. https://doi.org/10.1136/ARD.2007.071936 PubMed DOI

Lee T, Gasim A, Derebail VK et al (2014) Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol 9(5):905–913. https://doi.org/10.2215/CJN.08290813 PubMed DOI PMC

Pepper RJ, McAdoo SP, Moran SM et al (2019) A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 58(2):260–268. https://doi.org/10.1093/RHEUMATOLOGY/KEY288 PubMed DOI

Walters G, Willis NS, Craig JC (2015) Interventions for renal vasculitis in adults. Cochrane database Syst Rev. https://doi.org/10.1002/14651858.CD003232.PUB3 PubMed DOI PMC

Jones RB, Cohen Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211–220. https://doi.org/10.1056/NEJMOA0909169 PubMed DOI

Walters GD, Willis NS, Cooper TE, Craig JC (2020) Interventions for renal vasculitis in adults. Cochrane database Syst Rev. https://doi.org/10.1002/14651858.CD003232.PUB4 PubMed DOI PMC

Groot K, Harper L, Jayne DRW et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150(10):670 PubMed DOI

Adu D, Pall A, Luqmani RA et al (1997) Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90(6):401–409. https://doi.org/10.1093/QJMED/90.6.401 PubMed DOI

Unizony S, Villarreal M, Miloslavsky EM et al (2016) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75(6):1166–1169. https://doi.org/10.1136/ANNRHEUMDIS-2015-208073 PubMed DOI

Moura MC, Irazabal MV, Eirin A et al (2020) Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease. J Am Soc Nephrol 31(11):2688–2704. https://doi.org/10.1681/ASN.2019111197 DOI

McClure M, Gopaluni S, Jayne D, Jones R (2018) B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol 14(10):580–591. https://doi.org/10.1038/S41584-018-0065-X PubMed DOI

Charles P, Terrier B, Perrodeau É et al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77(8):1144–1150. https://doi.org/10.1136/ANNRHEUMDIS-2017-212878 DOI

Smith RM, Jones RB, Specks U et al (2020) Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 79(9):1243–1249. https://doi.org/10.1136/ANNRHEUMDIS-2019-216863 PubMed DOI

A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease - ACR Meeting Abstracts. Accessed 16 Jan 2022

Walsh M, Merkel PA, Peh C-A et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382(7):622–631. https://doi.org/10.1056/NEJMOA1803537/SUPPL_FILE/NEJMOA1803537_DATA-SHARING.PDF PubMed DOI PMC

Tuin J, Stassen PM, Bogdan DI et al (2019) Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody–associated vasculitis: Randomized, controlled trial. Clin J Am Soc Nephrol 14(7):1021–1028. https://doi.org/10.2215/CJN.11801018/-/DCSUPPLEMENTAL PubMed DOI PMC

De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(8):2461–2469. https://doi.org/10.1002/ART.21142 PubMed DOI

Walsh M, Catapano F, Szpirt W et al (2011) Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 57(4):566–574. https://doi.org/10.1053/J.AJKD.2010.10.049 PubMed DOI

Jayne DRW, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18(7):2180–2188. https://doi.org/10.1681/ASN.2007010090 PubMed DOI

Walsh M, Merkel PA, Peh CA et al (2013) Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14(1):73. https://doi.org/10.1186/1745-6215-14-73 PubMed DOI PMC

Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD (2004) Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66(4):1535–1540. https://doi.org/10.1111/J.1523-1755.2004.00917.X PubMed DOI

Jayne DRW, Merkel PA, Schall TJ, Bekker P (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384(7):599–609. https://doi.org/10.1056/NEJMOA2023386/SUPPL_FILE/NEJMOA2023386_DATA-SHARING.PDF PubMed DOI

Jayne DRW, Bruchfeld AN, Harper L et al (2017) Randomized trial of c5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28(9):2756–2767. https://doi.org/10.1681/ASN.2016111179 PubMed DOI PMC

Chung SA, Langford CA, Maz M et al (2021) Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 73(8):1088–1105. https://doi.org/10.1002/acr.24634 PubMed DOI

Walsh M, Merkel PA, Mahr A, Jayne D (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) 62(8):1166–1173. https://doi.org/10.1002/ACR.20176 PubMed DOI

Sanders JSF, De Joode AAE, Desevaux RG et al (2016) Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Nephrol Dial Transplant 31(9):1453–1459. https://doi.org/10.1093/NDT/GFW211 PubMed DOI

Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349(1):36–44. https://doi.org/10.1056/NEJMOA020286 PubMed DOI

Charles P, Perrodeau É, Samson M et al (2020) Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med 173(3):179–188. https://doi.org/10.7326/M19-3827 PubMed DOI

Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304(21):2381–2388. https://doi.org/10.1001/JAMA.2010.1658 PubMed DOI

Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. N Engl J Med 359(26):2790–2803. https://doi.org/10.1056/nejmoa0802311 PubMed DOI

Group TWGET (2009) Etanercept plus standard therapy for wegener’s granulomatosis. N Engl J Med 352(4):351–361. https://doi.org/10.1056/NEJMOA041884 DOI

Mikkel Faurschou, Inge Juul Sorensen, Lene Mellemkjaer, Anne Gitte Rasmussen Loft, Bjarne Svalgaard Thomsen, Niels Tvede BB. Malignancies in Wegener’s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. Accessed 16 Jan 2022.

Pendergraft WF, Cortazar FB, Wenger J et al (2014) Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with anca vasculitis. Clin J Am Soc Nephrol 9(4):736–744. https://doi.org/10.2215/CJN.07340713/-/DCSUPPLEMENTAL PubMed DOI PMC

Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Ruprecht HD (2004) ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 19:1403–1411. https://doi.org/10.1093/ndt/gfh161 PubMed DOI

Geetha D, Eirin A, True K et al (2011) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation 91(12):1370. https://doi.org/10.1097/TP.0B013E31821AB9AA PubMed DOI PMC

Hruskova Z, Tesar V, Geetha D (2020) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. Kidney Blood Press Res 45(2):157–165. https://doi.org/10.1159/000505660 PubMed DOI